St. Pete?s Biocad gets $8.6m government contracts for vital drug RandD

St. Pete?s Biocad gets $8.6m government contracts for vital drug RandDBiocad, a St. Petersburg-based biopharma, has won and signed four government contracts for the development of drugs to fight HIV, chronic B-type hepatitis, cancer, and blood coagulation disorders.

Biocad, a St. Petersburg-based biopharma, has won and signed four government contracts for drug-related R&D, Remedium.ru reports, citing a company source. The government is reportedly expected to pay the company a total of $8.6m to do the job. Under the terms of the contracts, Biocad will develop technologies and come up with methodologies to manufacture an antiretroviral synthetic drug to treat HIV; a peroral antiviral drug for chronic B-type hepatitis therapy; an antitumor immunomodulator possessing antiangiogenic properties, to be used in Kahler?s disease patients; and a drug to prevent and/or treat blood coagulation disorders caused by hereditary or acquired blood-coagulation factor VII deficit. All the four drugs to be developed using the government money are said to have never been manufactured by Russian pharmas and to be all protected by patents held by international companies that operate in Russia...